On August 28th, Morgan Stanley released a research report stating that after Shanghai Pharma announced its second-quarter results, it showed a decrease in sales of distribution and manufacturing businesses, a slight increase in business gross margin, and a decrease in operating expenses. Therefore, Morgan Stanley has lowered its profit forecast for the group in 2024 and 2025 by 9% and 3% respectively, while raising its profit forecast for 2026 to 2030 by 2% to 12%. The bank has also raised the target price for the group from HK$17.5 to HK$18.4 and maintained its 'shareholding' rating.
大行评级｜大摩：上调上海医药目标价至18.4港元 续予“增持”评级
Major rating|DBS: Upgrades sh pharma's target price to 18.4 Hong Kong dollars, reiterates "shareholding" rating.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated